A. Goy Et Al. , "Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.14, 2014
Goy, A. Et Al. 2014. Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.14 .
Goy, A., Williams, M. E., Besisik, S., Drach, J., Ramchandren, R., Zhang, L., ... Cicero, S.(2014). Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.14.
Goy, Andre Et Al. "Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study," CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.14, 2014
Goy, Andre Et Al. "Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.14, 2014
Goy, A. Et Al. (2014) . "Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study." CLINICAL LYMPHOMA MYELOMA & LEUKEMIA , vol.14.
@article{article, author={Andre Goy Et Al. }, title={Efficacy, Safety and Responder Subanalysis of Lenalidomide in Heavily Pretreated, Relapsed/Refractory Patients With Mantle Cell Lymphoma Post-Bortezomib: Phase II MCL-001 "EMERGE" Study}, journal={CLINICAL LYMPHOMA MYELOMA & LEUKEMIA}, year=2014}